TRIAMCINOLONE
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and anti-allergic effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
| Metabolism | Hepatic via cytochrome P450 3A4 (CYP3A4); undergoes reduction, hydroxylation, and conjugation; metabolites are excreted renally. |
| Excretion | Triamcinolone is primarily metabolized hepatically; unchanged drug and metabolites are excreted renally. Approximately 25-30% of a dose is excreted in urine as unchanged triamcinolone, with the remainder as metabolites. Fecal excretion accounts for less than 10%. |
| Half-life | The terminal elimination half-life of triamcinolone is approximately 2-5 hours (mean 3 hours) following intravenous administration. Clinically, this short half-life supports multiple daily dosing for systemic effects, but duration of action is longer due to receptor occupancy. |
| Protein binding | Triamcinolone is approximately 66-78% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (transcortin). |
| Volume of Distribution | The apparent volume of distribution is approximately 1.3-1.6 L/kg, indicating extensive tissue distribution (total body water exceeds 0.6 L/kg). |
| Bioavailability | Oral: approximately 15-40% due to first-pass metabolism (mean ~23%). Intramuscular: 100% (complete absorption). Topical: variable, typically 0.1-2% for intact skin; higher with damaged skin or occlusive dressings. |
| Onset of Action | Intravenous: immediate (within minutes); intramuscular: 30-60 minutes; oral: 1-2 hours; topical: variable, typically within hours for anti-inflammatory effect; intra-articular: 24-48 hours for relief of joint pain. |
| Duration of Action | The duration of action is dose- and route-dependent. For systemic effects, duration is 12-36 hours after a single IV or IM dose. Intra-articular injections provide relief for weeks (1-4 weeks). Topical effects last 4-12 hours depending on formulation and extent of application. |
| Molecular Weight | 434.5 |
Intramuscular: 40-80 mg as a single dose; Intra-articular: 5-40 mg depending on joint size; Topical: Apply thin layer 2-4 times daily; Oral: 4-48 mg/day in divided doses.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. In severe renal impairment (GFR <30 mL/min), use with caution due to increased risk of fluid retention; dose reduction or interval prolongation may be considered. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25-50% due to impaired metabolism. Child-Pugh C: Avoid use or reduce dose by 50-75% if necessary; monitor for toxicity. |
| Pediatric use | Intramuscular: 0.11-1.6 mg/kg/day in divided doses every 12-24 hours; Oral: 0.1-2 mg/kg/day divided every 6-12 hours; Topical: Apply sparingly 1-2 times daily; not for use in children <2 years except under specialist guidance. |
| Geriatric use | Start at lowest effective dose (e.g., oral 4 mg/day, topical once daily). Monitor for hyperglycemia, osteoporosis, and fluid retention. Avoid prolonged use due to increased risk of adverse effects. Consider dose reduction by 20-30% in frail elderly. |
| 1st trimester | Corticosteroids like triamcinolone are associated with a small increased risk of cleft palate when used in the first trimester. Use only if clearly needed and the benefit outweighs the risk. |
| 2nd trimester | Avoid systemic use unless necessary. Topical or inhaled forms may be used cautiously if indicated. |
| 3rd trimester | Use may lead to fetal adrenal suppression if used chronically near term. Avoid prolonged use. |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| Placental transfer | Triamcinolone crosses the placenta. The degree of transfer is moderate, with fetal concentrations approximately 10-70% of maternal serum levels. |
| Breastfeeding | Triamcinolone is excreted into breast milk in small amounts. Use with caution, especially with high doses or prolonged therapy. Monitor infant for signs of adrenal suppression. |
■ FDA Black Box Warning
None.
| Common Effects | Hyperglycemia |
| Serious Effects |
Systemic fungal infectionHypersensitivity to triamcinolone or any component
| Precautions | Increased risk of infections (bacterial, viral, fungal, protozoan), Adrenal suppression with prolonged use or abrupt withdrawal, Cushing's syndrome with high doses or long-term use, Osteoporosis with chronic use, Growth suppression in children, Glaucoma and cataracts (especially with ophthalmic use), Immunosuppression and risk of reactivation of latent infections (e.g., TB, hepatitis B, herpes zoster), Fluid and electrolyte disturbances (hypernatremia, hypokalemia, edema), Gastrointestinal perforation (especially in patients with GI disease), Muscle wasting and myopathy |
| Food/Dietary | None significant. May cause sodium retention and fluid retention at high doses; consider monitoring salt intake if edema develops. Grapefruit juice does not interact significantly. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. First trimester: Increased risk of cleft palate (odds ratio 1.3-3.3) based on human data; avoid use. Second/third trimesters: Risk of fetal adrenal suppression, intrauterine growth restriction, and preterm delivery with prolonged systemic use. Topical use considered low risk but high-potency agents should be limited. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal growth ultrasound every 4-6 weeks if prolonged use. Neonatal monitoring for adrenal suppression (electrolytes, glucose) if maternal dose >20 mg/day prednisone equivalent for >2 weeks before delivery. |
| Fertility Effects | No known significant adverse effects on fertility in animal studies or human data. May suppress ovulation at high doses via hypothalamic-pituitary-adrenal axis suppression; reversible upon dose reduction. |
| Clinical Pearls | For intra-articular injection, use a 25-gauge needle and inject into joint space after aspirating synovial fluid to confirm placement. Avoid overuse in weight-bearing joints to prevent corticosteroid-induced arthropathy. Monitor HPA axis suppression with long-term use; taper systemic doses gradually. Triamcinolone acetonide is the most potent ophthalmic formulation; reserve for non-infectious uveitis and avoid in viral or fungal infections. For intralesional use in keloids, mix with lidocaine to reduce injection site pain. |
| Patient Advice | Do not stop this medication abruptly; follow your doctor's tapering schedule. · Report any signs of infection (fever, redness, swelling) or worsening pain after joint injection. · Avoid live vaccines (e.g., MMR, nasal flu) while on high-dose or long-term therapy. · Inhaled forms: rinse mouth with water after use to prevent oral thrush. · Long-term use may increase risk of osteoporosis; ensure adequate calcium and vitamin D intake. |